Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19009790 | 0.84 | MKNK1 (0.33) | MEN1KMT2ADHODHADORA2ANUDT1 | |
| SCHEMBL19009838 | 0.79 | ACACA (0.34) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL19009841 | 0.78 | TOP1 (0.39) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL19009727 | 0.75 | ADORA2A (0.41) | KDM4EHPGDCYP3A4ADORA2A | |
| SCHEMBL19009804 | 0.73 | DHFR (0.40) | MEN1KMT2AKDM4EDHODHADORA2A | |
| SCHEMBL19020501 | 0.72 | ADORA2A (0.37) | MEN1KMT2AKDM4EALDH1A1ADORA2A | |
| SCHEMBL19726379 | 0.72 | MYC (0.46) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL19009766 | 0.72 | ALDH1A1 (0.37) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL19009724 | 0.72 | CYP11B1 (0.45) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL19009775 | 0.72 | TOP1 (0.36) | MEN1KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170179407-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170179407-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170179407-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | MEN1 611/4885KMT2A 2845/4885KDM4E 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.